| HS Code | 878701 |
| Product Name | Nitrofurazone Ointment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Cas Number | 59-87-0 |
| Molecular Formula | C6H6N4O4 |
| Molecular Weight | 198.14 g/mol |
| Appearance | Yellow crystalline powder |
| Solubility | Slightly soluble in water; sparingly soluble in ethanol; soluble in dimethylformamide |
| Melting Point | 236-240°C (with decomposition) |
| Assay Purity | 98.0% to 101.0% (on dried basis) |
| Storage Conditions | Store in tightly closed containers, protected from light, in a cool, dry place |
| Shelf Life | Typically 36 months when stored under recommended conditions |
| Veterinary Indications | Topical and systemic antibacterial agent for infections caused by Gram-positive and Gram-negative bacteria; effective against Escherichia coli, Staphylococcus, Streptococcus, and Salmonella |
| Dosage Form Compatibility | Suitable for formulation into ointments, tablets, injections, capsules, powders, granules, premixes, and solutions for veterinary use |
| Mechanism Of Action | Inhibits bacterial DNA synthesis by interfering with nucleic acid metabolic processes; bacteriostatic at low concentrations and bactericidal at higher concentrations |
As an accredited Nitrofurazone Ointment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packed in 25 kg double-lined drums, sealed for stability, with clear labeling for veterinary API handling. |
| Container Loading (20′ FCL) | A 20′ FCL containing Nitrofurazone veterinary-grade API in suitable sealed containers, ready for formulation into tablets, injections, capsules, powders, granules, premix, or solutions. |
| Shipping | Ship Nitrofurazone Veterinary Grade API in sealed, light-resistant containers to prevent degradation. Store in a cool, dry, well-ventilated area away from moisture and incompatible substances. Ensure proper labeling, secure packaging, and compliance with hazardous material regulations. Avoid extreme temperatures during transit to maintain product integrity and efficacy. |
| Storage | Store Nitrofurazone Veterinary Grade API in tightly sealed, light-resistant containers in a cool, dry, well-ventilated area. Protect from moisture, direct sunlight, and heat. Avoid contact with oxidizing agents. Maintain stable temperatures to preserve potency and purity for manufacturing tablets, injections, capsules, powders, granules, premix, and solutions. Use controlled storage conditions. |
| Shelf Life | Shelf Life: 24 months from manufacture when stored in tight, light-resistant containers, below 25°C, protected from moisture. |
Manufacture of nitrofurazone topical ointment for canine, feline, and equine wound management begins with the compendial specification for Nitrofurazone Ointment in the current USP monograph, which establishes a nominal active content of 0.2% w/w, equivalent to 2.0 mg of nitrofurazone per gram of finished semi-solid, and requires dispersion of the drug in a water-miscible polyethylene glycol vehicle composed of PEG 400 and PEG 3350 in proportions adjusted to produce a smooth, translucent ointment that spreads evenly over granulating tissue without occluding the wound bed. The industry compliance framework for this dosage form includes FDA 21 CFR Part 211 current good manufacturing practice regulations for finished pharmaceuticals, USP 〈621〉 HPLC assay methodology for nitrofurazone content uniformity and degradation product profiling, USP 〈661.1〉 plastic packaging suitability testing for light-resistant containers, and ICH Q3D elemental impurity control. The API is milled or jet-milled to a particle size distribution with D90 not exceeding 75 µm, because larger agglomerates produce content non-uniformity and visible yellow specks in translucent PEG bases, while over-milling below D90 10 µm increases electrostatic adhesion and dust generation during transfer. The downstream production process involves melting the PEG 3350 component in a 316L stainless-steel jacketed vessel fitted with PTFE scraper blades at 60–65°C, adding PEG 400 under overhead stirring at 100–150 rpm, then introducing the pre-sieved API through a 100-mesh stainless steel screen into the molten base to prevent localized agglomeration. A high-shear rotor-stator mixer operating at 3,000–5,000 rpm for 15–20 minutes is used to break remaining API agglomerates; the batch is then cooled from 60°C to 40°C at a controlled rate not exceeding 0.5°C/min with continued low-shear agitation to prevent API recrystallization at the vessel wall and to avoid air entrapment. Because nitrofurazone undergoes photochemical degradation under UV and visible light, intermediate bulk must be held in amber stainless-steel or glass-lined vessels, and final packaging must use amber glass jars or opaque plastic tubes with child-resistant closures where required. Terminal finished product types include 0.2% w/w nitrofurazone ointment in 14 g, 28 g, and 113 g tubes or jars for companion animal veterinary dispensing, labeled for non-food animals only.
In sterile veterinary ophthalmology, manufacturers of nitrofurazone ophthalmic ointments at 0.2% w/w for the treatment of bacterial conjunctivitis in dogs, cats, and horses operate under FDA 21 CFR Part 211 sterile drug manufacturing requirements, with sterility assurance demonstrated by USP 〈71〉 membrane filtration testing, antimicrobial effectiveness per USP 〈51〉, and metal particulate control per USP 〈751〉, which limits metal particles to not more than 50 particles of 50 µm or greater and not more than 8 particles of 100 µm or greater per 10 ointment tubes. The API particle size for ophthalmic application is more restrictive than for topical wound ointments, with D90 not exceeding 20 µm to eliminate corneal irritation and to ensure uniform drug distribution across the ocular surface; particle size analysis is performed by laser diffraction per USP 〈429〉. The formulation addition ratio is fixed at 0.2% w/w in a sterile petrolatum–mineral oil base or a sterile PEG-based ointment base; the base is sterilized by dry heat at 150°C for 120 minutes in stainless-steel trays, while the API is incorporated through aseptic powder transfer after validated sterilization of the API, with post-irradiation assay and impurity profiling to confirm no degradation, because terminal dry-heat sterilization of the complete ointment is generally avoided due to limited published long-term thermal stability data for nitrofurazone at 150°C. The downstream production process is conducted under ISO Class 5 unidirectional airflow within an ISO Class 7 cleanroom; the sterilized base is melted at 60–65°C, the sterile API is added through a sterile 100-mesh screen, and dispersion is completed with a sterile high-shear mixer before cooling to 40°C and filling into pre-sterilized 3.5 g ophthalmic tubes with sterile ophthalmic tips. Terminal finished product types include 0.2% w/w sterile ophthalmic ointment in 3.5 g aluminum or polyethylene ophthalmic tubes for non-food animal use only.
Equine wound irrigation solutions are formulated at 0.2% w/v nitrofurazone, corresponding to 2.0 mg of API per milliliter of finished solution, prepared under FDA 21 CFR Part 211 with release testing by USP 〈621〉 HPLC and packaging evaluated per USP 〈661.1〉 for light-resistant amber bottles. The API is dissolved in a propylene glycol or propylene glycol–water co-solvent system; published solubility data indicate that the saturation limit in pure propylene glycol at 25°C is reported to be above the 2.0 mg/mL target concentration without precipitation, but addition of water beyond 30% v/v reduces the solubility margin and may produce crystal growth during refrigerated storage at 4°C. The downstream production process involves adding the micronized API to propylene glycol in a stainless-steel mixing vessel heated to 40–50°C, with overhead agitation at 200–300 rpm for 60–90 minutes to achieve complete dissolution; the solution is then cooled to 25°C, filtered through a 10 µm stainless-steel cartridge filter to remove undissolved API aggregates, and filled into amber HDPE bottles under nitrogen blanketing to minimize oxidative degradation. Because nitrofurazone is photolabile, all filling lines must be equipped with low-UV amber shielding, and the finished product must be stored in cartons to limit light exposure during distribution. Terminal finished product types include 0.2% w/v nitrofurazone topical solution in 118 mL and 473 mL amber bottles for equine wound flushing and skin irrigation, labeled for horses not intended for human consumption.
| Standard / Designation | Title / Scope | Applicable Dosage Form |
|---|---|---|
| USP 〈621〉 | Chromatography (HPLC assay and impurity profiling) | All dosage forms |
| USP 〈661.1〉 | Plastic packaging suitability | Topical solutions, dusting powders, oral solids |
| USP 〈71〉 | Sterility testing | Ophthalmic ointment |
| USP 〈51〉 | Antimicrobial effectiveness testing | Ophthalmic ointment |
| USP 〈751〉 | Metal particles in ophthalmic ointments | Ophthalmic ointment |
| USP 〈429〉 | Light diffraction measurement of particle size | Ophthalmic and topical ointments |
| FDA 21 CFR Part 211 | CGMP for finished pharmaceuticals | All commercial dosage forms |
| FDA 21 CFR 530.41 | Prohibited extra-label drugs in food-producing animals | Regulatory boundary for all scenarios |
| EU Commission Regulation (EU) No 37/2010 | Pharmacologically active substances and maximum residue limits | Regulatory boundary for food-producing animals |
| ICH Q3D | Elemental impurities | All dosage forms |
| ICH Q8 | Pharmaceutical development (quality by design) | Oral solid dosage forms |
Because ornamental fish species are excluded from food-producing animal definitions in several national veterinary drug regulatory frameworks, finished powders containing nitrofurazone for aquarium use must be labeled and distributed exclusively for non-food ornamental fish, with supply-chain documentation confirming that treated animals and effluent water cannot enter the human food chain. The nitrofuran metabolite semicarbazide (SEM) is subject to zero-tolerance residue monitoring in aquaculture products intended for human consumption under EU Commission Decision 2002/657/EC and the FDA 21 CFR 530.41 prohibition on extra-label use in food-producing animals, so manufacturers must maintain separate batch records and distribution logs for aquarium-grade material. The API is incorporated into water-dispersible powder blends at 0.1–0.3% w/w in a carrier system of sodium chloride, dextrose, or polyvinylpyrrolidone, selected to achieve rapid dissolution and even distribution in aquarium water without the use of lactose or other reducing sugars that can react with the semicarbazone group of the API via Maillard-type condensation. The downstream production process involves dry blending in a V-blender operating at 20–30 rpm for 15–20 minutes, with environmental relative humidity controlled below 40% RH to prevent API hydrolysis and carrier caking; the blend is passed through a 60-mesh stainless-steel screen and filled into foil-lined sachets under nitrogen flush to exclude oxygen and light. Terminal finished product types include water-dispersible powder sachets ranging from 5 g to 100 g for immersion bath preparation in ornamental fish aquaria; label claims must state that the product is not for use in fish intended for human consumption.
When wet-wound management requires a dry application form that absorbs exudate while releasing API at the wound surface, a talc–starch dusting powder containing nitrofurazone is manufactured at an API addition ratio of 0.2% w/w, with the carrier blend composed of talc and absorbable starch in proportions selected to achieve a moisture uptake capacity that keeps the wound surface dry without forming a crust that seals in exudate. The compliance framework for this dosage form includes USP 〈795〉 for non-sterile compounding when prepared in pharmacy settings, or FDA 21 CFR Part 211 when manufactured as a commercial finished drug product, with assay by USP 〈621〉 HPLC and packaging in light-resistant containers per USP 〈661.1〉. The carrier blend is dried at 80–90°C to a moisture content below 1% w/w before blending, because residual moisture promotes starch swelling and API hydrolysis during storage. The downstream production process uses geometric dilution: the API is first triturated with an equal weight of carrier, then the mixture is successively doubled with carrier until the full batch size is reached, followed by blending in a V-blender at 20–30 rpm for 10–15 minutes and screening through a 60-mesh stainless-steel sieve to ensure content uniformity. Environmental relative humidity is maintained below 35% RH during blending and filling. Terminal finished product types include 0.2% w/w nitrofurazone dusting powder in 50 g and 100 g polyethylene jars with perforated dispensing caps, labeled for non-food animals only.
| Dosage Form | API Loading | D90 Particle Size | Critical Process Parameter | Packaging Configuration |
|---|---|---|---|---|
| Topical wound ointment | 0.2% w/w | ≤75 µm | Cooling rate ≤0.5°C/min | 14–113 g amber tubes or jars |
| Ophthalmic ointment | 0.2% w/w | ≤20 µm | Aseptic powder transfer | 3.5 g ophthalmic tubes |
| Topical solution | 0.2% w/v (2.0 mg/mL) | Fully dissolved | Dissolution at 40–50°C | 118–473 mL amber bottles |
| Aquarium immersion powder | 0.1–0.3% w/w | ≤75 µm | RH <40% during blending | 5–100 g foil-lined sachets |
| Dusting powder | 0.2% w/w | ≤75 µm | Carrier moisture <1% w/w | 50–100 g polyethylene jars |
| Avian oral solids | Development-dependent | Dry mill screen 0.8 mm | Drying temperature ≤50°C | Amber HDPE bottles |
For non-food avian species, oral solid dosage forms containing nitrofurazone occupy a narrow regulatory niche, because the same nitrofuran residue monitoring frameworks that govern food-producing animals—EU Commission Regulation (EU) No 37/2010 and FDA 21 CFR 530.41—create zero-tolerance enforcement for semicarbazide marker residues in any animal entering the human food chain; racing pigeons and caged birds are classified as non-food animals in some national registries, but the finished product sponsor must verify this classification in the destination market before registration. Published reference formulations for nitrofurazone tablets, capsules, and granules in avian species are limited; the API-to-excipient ratio in tablet cores is governed by the target unit dose, and this specific configuration requires development-scale validation under ICH Q8 quality-by-design principles. The downstream production process follows a standard low-dose veterinary solid dosage route: wet granulation with a polyvinylpyrrolidone binder solution in a high-shear granulator, tray drying at temperatures not exceeding 50°C to preserve API stability, dry milling through a 0.8 mm screen, and compression on a rotary tablet press equipped with light-protective dust extraction. Because nitrofurazone is photolabile, tablet cores are film-coated with an opaque light-protective coating or filled into amber HDPE bottles. Terminal finished product types include tablets and granules for drinking water administration in non-food avian species; all label claims must state that the product is not for use in animals intended for human consumption.
Competitive Nitrofurazone Ointment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Bulk nitrofurazone supplied for veterinary compounding is the semicarbazone derivative of 5-nitro-2-furaldehyde, CAS 59-87-0, molecular formula C6H6N4O4, and molecular weight 198.14 g/mol. The material is a yellow crystalline powder with a characteristic melting range of 236 °C to 240 °C with decomposition. Pharmacopoeial grade is controlled against the nitrofurazone monograph such as USP-NF, and the product is offered as a non-sterile veterinary API in micronized grades suitable for ointments, dry powders, granules, premixes, non-aqueous solutions, and, with significant formulation constraints, tableted or encapsulated preparations. The exact grade designation is manufacturer-specific; the critical physical attribute for downstream processing is not the model code but the particle-size distribution and the corresponding certificate of analysis. Nitrofurazone is practically insoluble in water, sparingly soluble in ethanol, and soluble in polyethylene glycol 400 and dimethylformamide. This solubility profile dictates the manufacturing route for each dosage form. Ointments are manufactured by pre-wetting the micronized API in a portion of PEG 400 or propylene glycol before dilution into a polyethylene glycol base, whereas aqueous solutions require co-solvent systems or pH adjustment that must be evaluated for precipitation, tissue tolerability, and hydrolytic degradation. The product differs from nitrofurantoin and furazolidone by its 5-nitrofuran nucleus with a semicarbazone side chain. That structural feature confers broad antibacterial activity but also produces a well-documented potential for genotoxic and carcinogenic residues. Because of residue concerns, nitrofurazone is prohibited for use in food-producing animals in multiple jurisdictions. Bulk handling requires engineering controls, light-resistant packaging, and occupational exposure review consistent with a potent nitrofuran API.
The USP-NF monograph for nitrofurazone sets release criteria for identity, melting range, loss on drying, residue on ignition, and assay. Melting range is determined by the capillary method and is accepted at 236 °C to 240 °C with decomposition. Loss on drying is typically not more than 0.5% when dried at 105 °C for 2 h, and residue on ignition is not more than 0.1%. Assay is 98.0% to 102.0% on the dried basis. Identification is established by infrared absorption spectrophotometry against the current USP reference standard and by ultraviolet absorption characteristics. A veterinary API certificate of analysis should also include residual solvents under USP <467> or ICH Q3C options, elemental impurities under ICH Q3D or USP <232>/<233>, sulfated ash, and particle-size distribution by laser diffraction when the API is micronized. Because nitrofurazone is light-sensitive, bulk packaging must be light-resistant and storage should be maintained at controlled room temperature not exceeding 25 °C with protection from moisture. The manufacturer-assigned retest period, commonly 24 to 36 months in sealed double polyethylene bags inside fiber drums, must be supported by stability data under ICH Q1A conditions. Table 1 summarizes typical batch-release parameters for the veterinary API.
| Parameter | Acceptance criterion | Test method/reference |
|---|---|---|
| Appearance | Yellow crystalline powder, free from visible contamination | Visual examination |
| Identification | Infrared spectrum corresponds to reference standard; ultraviolet maxima match | Monograph identity test |
| Melting range | 236–240 °C with decomposition | USP <741> |
| Loss on drying | NMT 0.5% | USP <731> |
| Residue on ignition | NMT 0.1% | USP <281> |
| Assay, dried basis | 98.0–102.0% | HPLC or UV per monograph |
| Elemental impurities | Limits per ICH Q3D or USP <232>/<233> | ICP-MS |
| Particle size, micronized grade | Manufacturer specification for D90 or D50 | Laser diffraction, USP <429> |
| Residual solvents | Class 2/Class 3 within ICH Q3C options | Headspace GC, USP <467> |
For topical veterinary ointments, the most common strength is 0.2% w/w nitrofurazone in a water-miscible base composed of PEG 400 and PEG 3350. The processing routine is a pre-dispersion of the micronized API in PEG 400 at a jacket temperature not exceeding 40 °C using a vacuum planetary mixer. Anchor speed is typically limited to 25–40 rpm, with homogenizer speed below 1,500 rpm to prevent localized thermal degradation and particle re-agglomeration. The dispersion is then transferred to a molten PEG 3350 phase and mixed under vacuum to avoid air entrapment. Batch filtration through a 150 µm in-line strainer removes agglomerates that would otherwise cause content non-uniformity in small tubes. Production-scale behavior on vertical planetary mixers has shown that adding API powder directly to the molten base without pre-wetting produces visible yellow specks and content-uniformity failures at the beginning and end of filling runs. Published data for this specific configuration is limited, but the pre-wetting requirement is consistent with the poor aqueous solubility of nitrofurazone. For dry powder and granule formulations intended for topical wound dressings, a stepwise geometric dilution is used to achieve blend uniformity. Direct compression of nitrofurazone tablets is complicated by the API’s low aqueous solubility and light sensitivity, while wet granulation with aqueous binders requires amber processing areas, controlled humidity, and prompt drying to maintain chemical stability.
Formulation into oral tablets or capsules is technically feasible by direct blending with lactose monohydrate or microcrystalline cellulose, but regulatory restrictions make such products inappropriate for food-producing species. In the United States, extra-label use of nitrofurazone in food-producing animals is prohibited under 21 CFR 530.41. In the European Union, nitrofurans including nitrofurazone are classified as prohibited substances with no maximum residue limit for food-producing animals; detection of the parent drug or the semicarbazide marker in edible tissue is treated as non-compliance under Commission Regulation (EU) No 37/2010. For companion animals, the marketed form remains predominantly a topical 0.2% ointment. Injectable formulations face additional constraints. Nitrofurazone is practically insoluble in water and requires co-solvents such as N,N-dimethylacetamide, propylene glycol, or PEG 400. Aqueous co-solvent systems can precipitate upon injection and cause tissue irritation. Steam sterilization at 121 °C accelerates hydrolytic degradation unless the pH is maintained between 4.0 and 6.0. Terminal sterilization data for nitrofurazone injections in target species are limited; aseptic filtration of non-aqueous solutions through 0.22 µm filters is an alternative but requires filter compatibility testing because of co-solvent effects. Amber glass or opaque packaging is mandatory, and any injectable formulation must be developed under a veterinarian’s responsibility with residue-risk and tissue-reaction assessments where applicable.
Powders, granules, and premixes containing nitrofurazone are most commonly encountered as topical dusting preparations or non-sterile compounding intermediates. For topical powders, the micronized API is blended with absorbable starch, lactose, or a mineral carrier using tumble or ribbon blenders. Segregation risk increases when the API particle size is not matched to the carrier; laser-diffraction data and bulk-density measurements are therefore more operationally useful than the label claim alone. Feed premixes for food-producing animals are not legally acceptable in major regulatory jurisdictions because of the same residue prohibition. Solutions are generally non-aqueous topical products based on propylene glycol, PEG 400, or a mixture of these solvents. Water addition, if required for solubility or wetting, must be limited and buffered to the acidic range because semicarbazone hydrolysis releases 5-nitro-2-furaldehyde and semicarbazide. The semicarbazide impurity is analytically significant because it is used as a marker for nitrofurazone exposure in food-animal residue monitoring. Bulk release testing alone is not sufficient to control residue risk; finished-product formulators must also evaluate the regulatory status of the target species and the intended route.
Nitrofurazone degradation in solid and solution states follows nitro group reduction, Schiff-base hydrolysis, and photochemical reduction pathways. The semicarbazone linkage is susceptible to acid-catalyzed hydrolysis, releasing 5-nitro-2-furaldehyde and semicarbazide. Alkaline conditions accelerate decomposition, and pharmaceutical processing therefore maintains aqueous-based formulations between pH 4.0 and 6.0. Thermal degradation becomes significant above 40 °C during prolonged exposure in polyethylene glycol bases; the product darkens from yellow to orange-brown. Photodegradation occurs under ultraviolet and visible light, requiring amber lighting and light-resistant containers. For dry powders, moisture absorption above 60% relative humidity can promote hydrolysis at particle surfaces during wet granulation. Granulation should be completed promptly and dried to a final moisture content below 2.0% if a tablet or capsule is manufactured. Because fine powder can form combustible dust clouds, milling and sieving operations should be conducted with local exhaust and assessed against applicable ATEX or NFPA guidance. These constraints are more stringent than those for many non-nitrofuran topical antibacterials because of the API’s chromophore sensitivity and genotoxicity profile. Addition of chelating agents or antioxidants is not generally used in simple 0.2% ointments because the non-aqueous base limits hydroperoxide formation, but any antioxidant selection must be confirmed by forced-degradation studies under ICH Q1B or equivalent photostability conditions. The absence of published forced-degradation data for each custom formulation should be treated as a critical quality gap rather than an assumption of stability.
Nitrofurazone belongs to the nitrofuran class and is characterized by a 5-nitrofuran ring attached to a semicarbazone moiety. Furazolidone contains an oxazolidinone substituent, and nitrofurantoin contains an imidazolidinedione ring. The structural difference alters solubility, pharmacokinetic behavior, and clinical placement. Nitrofurantoin is used primarily in human urinary tract infections, whereas furazolidone has been used historically as an oral enteric antibacterial in non-food animals but shares the same residue and mutagenicity concerns. Nitrofurazone is used almost exclusively as a topical veterinary ointment because systemic absorption is limited through intact skin but increases through abraded or burned tissue. The product differs from chlorhexidine or silver sulfadiazine topical preparations by its mechanism of action, which requires reductive activation of the nitro group to reactive intermediates that inhibit bacterial DNA, RNA, and protein synthesis. This mechanism gives broad gram-positive and gram-negative coverage but also produces the same reactive intermediates that underlie genotoxicity in mammalian cells. Published minimum inhibitory concentration distributions for nitrofurazone against veterinary wound pathogens are less frequently updated in current CLSI documents than those for fluoroquinolones or aminoglycosides. Susceptibility interpretation should therefore follow historical laboratory reference data or a local antibiogram. Unlike silver sulfadiazine, nitrofurazone is not the first-choice agent for deep burn sepsis in many current veterinary formularies because of potential systemic absorption from large denuded areas. Table 2 summarizes comparative properties relevant to selection.
| Attribute | Nitrofurazone | Furazolidone | Nitrofurantoin |
|---|---|---|---|
| Molecular formula | C6H6N4O4 | C8H7N3O5 | C8H6N4O5 |
| Molecular weight | 198.14 g/mol | 225.16 g/mol | 238.16 g/mol |
| Melting range | 236–240 °C with decomposition | 253–255 °C with decomposition | 268–270 °C with decomposition |
| Water solubility | Practically insoluble | Practically insoluble | Practically insoluble |
| Primary dosage form | Topical 0.2% ointment | Historical oral preparation | Human oral capsule/suspension |
| Key regulatory restriction | Prohibited in food animals, 21 CFR 530.41; EU No 37/2010 | Prohibited in food animals, 21 CFR 530.41; EU No 37/2010 | Not approved for food animals; residue concern |
| Marker residue | Semicarbazide | AOZ | AHD |
For compounding pharmacies and veterinary drug manufacturers, the API is usually received in double polyethylene bags inside a sealed fiber drum. A nitrogen atmosphere is not mandatory for all logistics, but long-term storage under nitrogen reduces oxidative discoloration. On receipt, the material should be quarantined and sampled according to ANSI/ASQ Z1.4 or an equivalent sampling plan. Because the API is potent and potentially genotoxic, sampling booths with high-efficiency particulate air filtration and appropriate personal protective equipment should be used. Bulk API should be dispensed into amber glass vials or light-resistant containers for laboratory-scale compounding, and secondary packaging must prevent moisture migration. Stocks should be rotated on a first-expiry, first-out basis. Any material exhibiting darkened color, visible agglomerates that cannot be broken by light sieving, or an odor indicative of decomposition should be rejected. These receiving and storage controls are especially important for a nitrofuran derivative because photolytic and hydrolytic degradation products are not always separated from the parent compound by simple visual inspection, and their presence may not be detected by compendial assay alone.
